| Grant number: | 17/21453-4 |
| Support Opportunities: | Scholarships in Brazil - Scientific Initiation |
| Effective date (Start): | April 01, 2018 |
| Effective date (End): | March 31, 2019 |
| Field of knowledge: | Health Sciences - Medicine - Surgery |
| Principal Investigator: | Raquel Franco Leal |
| Grantee: | Renato Lazarin Ricci |
| Host Institution: | Faculdade de Ciências Médicas (FCM). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil |
Abstract Crohn's disease (DC) is characterized by recurrent chronic transmural inflammation, which can affect any segment of the gastrointestinal tract from the mouth to the anus, especially the ileal segment. The etiology is not well known, however, environmental factors in genetically susceptible individuals are associated with the disease, resulting in an inappropriate immune response. The introduction of biological agents to treat inflammatory bowel diseases (IBD), because of their capability to promote mucosal healing, has modified the natural process of the disease, with a tendency to decrease surgeries and/or hospitalizations. Although they are not yet widely available in Brazil, the measurement of through levels of Infliximab (IFX), which is an anti-TNF±, as well as, the detection of anti-IFX antibody would be indispensable in the therapeutic handling of CD patients. These tolls may help in the adjusting of therapeutic dose, and also may help in the biological non-response understanding. The method will be quantitative and cross-sectional study. We will study 40 CD patients, between 18 to 60 years old, of both genders, who are being followed-up at the IBD outpatient clinic, Gastrocenter - UNICAMP, and who are making continuous and regular use of IFX. The IFX through levels measurement and the detection of anti-IFX antibody will be performed by the ELISA method. The comparison of these levels among the groups will be performed according to the degree of endoscopic and/or radiological activity of the disease. The present study was approved by the UNICAMP Research Ethics Committee. For statistical analysis, non-parametric tests will be used. The level of significance adopted will be 5%. From these analyses, we expect to better understand the loss of response to the biological agents in this group of patients, by analyzing the anti-TNF± levels and the patients who have developed drug immunogenicity. (AU) | |
| News published in Agência FAPESP Newsletter about the scholarship: | |
| TITULO | |
| Articles published in other media outlets (0 total): | |
| More itemsLess items | |
| VEICULO: TITULO (DATA) | |
| VEICULO: TITULO (DATA) | |